Two rare FGFR alterations have been consistently reported in gliomas: fusions involving the families of genes FGFR and TACC (mostly FGFR3-TACC3) [57,58], and hotspot mutations N546 and K656 in FGFR1 gene [59], showing a major therapeutic convergence from the possibility of treating patients with targeted anti-FGFR compounds. This evidence concerns the gene FGFR3 and central nervous system cancer.